Angiogenesis Inhibitors in Clinical Trials Open to Men with Prostate Cancer: Expanded Trial Information
This page provides links to the trial descriptions for a selection of those antiangiogenesis trials included in the NCI trials database.
AG3340:
- Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer (Protocol ID: AG-3340-009)
COL-3:
-
Phase I Study of COL-3 in Patients with Advanced Solid Tumors (Protocol ID: UTHSC-9785011153, NCI-T97-0091, SACI-IDD-97-27)
- J Pharm Biomed Anal 2000 Jul;22(6):1003-14
High-performance liquid chromatography with mass
spectrometry detection for quantitating COL-3, a chemically
modified tetracycline, in human plasma.
Rudek MA, March CL, Bauer KS Jr, Pluda JM, Figg WD
Medicine Branch, Division of Clinical Sciences, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892, USA.
- Drugs 2000 May;59(5):1043-55
Clinical potential of matrix metalloprotease inhibitors in
cancer therapy.
Heath EI, Grochow LB
Division of Medical Oncology, Johns Hopkins Oncology Center, Baltimore,
Maryland 21231, USA. [email protected]
-
Cancer Lett 2000 May 29;153(1-2):75-8
Effects of tetracyclines on angiogenesis in vitro.
Fife RS, Sledge GW Jr, Sissons S, Zerler B
Department of Medicine, Indiana University School of Medicine, 535 Barnhill
Dr., Indianapolis, IN 46202, USA. [email protected]
- Cancer Control 1999 Oct;6(5):459-465 Review of Three New Agents That Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases. Lush RM, Rudek MA, Figg WD Department of Research Administration, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Preclinical reports: COL-3, also called metastat, is a matrix metalloproteinase inhibitor derived from modified tetracycline. The Phase I chief investigator is Eric Keith Rowinsky. To see abstracts of other studies he has worked on click here and put into the form Rowinksy EK and/or Rowinsky EK, prostate
Thalidomide:
- Thalidomide and Cyclophosphamide in Treating Patients with Recurrent or Refractory Cancer (Protocol ID; MSKCC-98088, NCI-G99-1498, MSKCC-98088A(1))
- Phase III Randomized Study of Oral Thalidomide Versus Placebo in Patients With Androgen Dependent Stage IV Nonmetastatic Prostate Cancer Following Limited Hormonal Ablation (Protocol ID: NCI-00-C-0080, NCI-T99-0053)
Combrestatin A-4 Prodrug:
- Chemotherapy in Treating Patients with Solid Tumors (Protocol ID: CRC-PHASE-I/II-PHI/066, EU-98066)
- Phase I Study of Combretastatin A4 Phosphate in Patients With Advanced Solid Tumors (Protocol ID: CWRU-ILEX-1Y98, NCI-G99-1502, ILEX-1Y98, ILEX-CA4P101-A3)
Endostatin:
- Phase I Study in Patients With Advanced Solid Tumors (Protocol ID: MDA-ID-99201, NCI-T99-0087)
- Phase I Study of Endostatin in Patients With Advanced Refractory Solid Tumors (Protocol IDs: WCCC-CO-99910, NCI-T99-0055)
SU5416:
- Phase I Study of SU5416 in Patients With Advanced Solid Tumors (Protocol ID: CWRU-2Y99, NCI-T99-0095)
- Phase I Study of SU5416 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (Protocol ID: UCLA-0002046, NCI-G00-1805, SUGEN-ND019901/SE5416.102)
- Phase I Study of SU5416 With Irinotecan and Cisplatin in Patients With Advanced Solid Tumors (Protocol ID: OSU-00H0033, NCI-47)
- Phase II Randomized Study of SU5416 Versus Dexamethasone in Patients With Hormone Refractory Prostate Cancer (Protocol ID: UCCRC-NCI-49, NCI-49)
Anti-VEGF Antibody:
- Phase I Study of Monoclonal Antibody VEGF in Patients With Relapsed or Refractory Progressive Solid Tumors (Protocol ID: EORTC-13992, PDL-833-601)
EMD 121974:
- Phase I Study in Patients With Advanced or Metastatic Cancer (Protocol ID: IUMC-9909-40, NCI-T99-0076)
CAI:
- Carboxyamidotriazole and Paclitaxel in Treating Patients with Advanced Solid Tumors (Protocol ID: NCI-95-C-0015F, NCI-T94-0006N, NCI-CPB-334)
- Carboxyamidotriazole in Treating Patients with Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (Protocol ID: NCI-98-C-0012, NCI-T97-0112)
These are extracted from a complete list which NCI last updated 07/31/00
NCI Anti-Angiogenesis Main Page